460 related articles for article (PubMed ID: 29047372)
1. Effectiveness and safety of dipeptidyl peptidase 4 inhibitors in the management of type 2 diabetes in older adults: a systematic review and development of recommendations to reduce inappropriate prescribing.
Schott G; Martinez YV; Ediriweera de Silva RE; Renom-Guiteras A; Vögele A; Reeves D; Kunnamo I; Marttila-Vaara M; Sönnichsen A
BMC Geriatr; 2017 Oct; 17(Suppl 1):226. PubMed ID: 29047372
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of metformin in the management of type 2 diabetes mellitus in older adults: a systematic review for the development of recommendations to reduce potentially inappropriate prescribing.
Schlender L; Martinez YV; Adeniji C; Reeves D; Faller B; Sommerauer C; Al Qur'an T; Woodham A; Kunnamo I; Sönnichsen A; Renom-Guiteras A
BMC Geriatr; 2017 Oct; 17(Suppl 1):227. PubMed ID: 29047344
[TBL] [Abstract][Full Text] [Related]
3. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
Gooßen K; Gräber S
Diabetes Obes Metab; 2012 Dec; 14(12):1061-72. PubMed ID: 22519906
[TBL] [Abstract][Full Text] [Related]
4. Safety of dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
Doni K; Bühn S; Weise A; Mann NK; Hess S; Sönnichsen A; Pieper D; Thürmann P; Mathes T
Ther Adv Drug Saf; 2022; 13():20420986211072383. PubMed ID: 35111291
[TBL] [Abstract][Full Text] [Related]
5. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of beta blockers in the management of hypertension in older adults: a systematic review to help reduce inappropriate prescribing.
Vögele A; Johansson T; Renom-Guiteras A; Reeves D; Rieckert A; Schlender L; Teichmann AL; Sönnichsen A; Martinez YV
BMC Geriatr; 2017 Oct; 17(Suppl 1):224. PubMed ID: 29047367
[TBL] [Abstract][Full Text] [Related]
7. Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis.
Salvo F; Moore N; Arnaud M; Robinson P; Raschi E; De Ponti F; Bégaud B; Pariente A
BMJ; 2016 May; 353():i2231. PubMed ID: 27142267
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of dipeptidyl peptidase-4 inhibitors use and cardiovascular risk in patients with type 2 diabetes mellitus.
Kaneko M; Narukawa M
Diabetes Res Clin Pract; 2016 Jun; 116():171-82. PubMed ID: 27321333
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes.
Geng J; Yu H; Mao Y; Zhang P; Chen Y
Pharmacoeconomics; 2015 Jun; 33(6):581-97. PubMed ID: 25736235
[TBL] [Abstract][Full Text] [Related]
10. Short-term and long-term effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with renal impairment: a meta-analysis of randomized controlled trials.
Li R; Wang R; Li H; Sun S; Zou M; Cheng G
Diabetes Metab Res Rev; 2016 Sep; 32(6):460-9. PubMed ID: 26433213
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus.
Chen XW; He ZX; Zhou ZW; Yang T; Zhang X; Yang YX; Duan W; Zhou SF
Clin Exp Pharmacol Physiol; 2015 Oct; 42(10):999-1024. PubMed ID: 26173919
[TBL] [Abstract][Full Text] [Related]
12. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies.
Li L; Li S; Deng K; Liu J; Vandvik PO; Zhao P; Zhang L; Shen J; Bala MM; Sohani ZN; Wong E; Busse JW; Ebrahim S; Malaga G; Rios LP; Wang Y; Chen Q; Guyatt GH; Sun X
BMJ; 2016 Feb; 352():i610. PubMed ID: 26888822
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus patients with severe renal impairment: a meta-analysis.
Chen M; Liu Y; Jin J; He Q
Ren Fail; 2016; 38(4):581-7. PubMed ID: 26915531
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and patient safety of platelet aggregation inhibitors in the prevention of cardiovascular disease and ischemic stroke in older adults - a systematic review.
Meinshausen M; Rieckert A; Renom-Guiteras A; Kröger M; Sommerauer C; Kunnamo I; Martinez YV; Esmail A; Sönnichsen A
BMC Geriatr; 2017 Oct; 17(Suppl 1):225. PubMed ID: 29047342
[TBL] [Abstract][Full Text] [Related]
15. Synthetic and phytocompounds based dipeptidyl peptidase-IV (DPP-IV) inhibitors for therapeutics of diabetes.
Singh AK; Jatwa R; Purohit A; Ram H
J Asian Nat Prod Res; 2017 Oct; 19(10):1036-1045. PubMed ID: 28351157
[TBL] [Abstract][Full Text] [Related]
16. Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
Li N; Wang LJ; Jiang B; Li XQ; Guo CL; Guo SJ; Shi DY
Eur J Med Chem; 2018 May; 151():145-157. PubMed ID: 29609120
[TBL] [Abstract][Full Text] [Related]
17. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review.
Deacon CF
Diabetes Obes Metab; 2011 Jan; 13(1):7-18. PubMed ID: 21114598
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl peptidase IV inhibitors as a potential target for diabetes: patent review (2015-2018).
Hussain H; Abbas G; Green IR; Ali I
Expert Opin Ther Pat; 2019 Jul; 29(7):535-553. PubMed ID: 31203700
[TBL] [Abstract][Full Text] [Related]
19. A set of systematic reviews to help reduce inappropriate prescribing to older people: study protocol.
Martinez YV; Renom-Guiteras A; Reeves D; Erandie Ediriweera de Silva R; Esmail A; Kunnamo I; Rieckert A; Sommerauer C; Sönnichsen A
BMC Geriatr; 2017 Oct; 17(Suppl 1):231. PubMed ID: 29047332
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
